7 Best Peptides for Appetite

What to Know Before Choosing a Peptide for Appetite

Appetite is one of the most active areas in all of peptide research right now. The field spans FDA-approved medications available by prescription, investigational compounds in late-stage clinical trials, and a smaller set of research-only peptides discussed in community protocols. A compound earns a place on this list because people are genuinely using it or actively discussing using it for appetite control, not because it cleared a particular evidence bar. That means FDA-approved, telemedicine-prescribed, and research-only compounds are all represented here, with the honesty of the evidence stated plainly for each one.

The numbers in front of each entry are a spine for the list, not a verdict. The order reflects how prominently each compound appears in the research literature and in real-world use, not a recommendation that one option is better for you than another. Two compounds at the top of this list have large randomized controlled trials and FDA approval behind them. Others are investigational, with compelling Phase 2 data but no approval yet. Still others sit in the research-chemical category, used in community protocols with limited or no published human data. All of them belong on a complete list of what people reach for when the goal is appetite control, and all of them are described as honestly as the evidence allows.

One framing note before you read: most of the peptides discussed here are appetite suppressants, because that is the dominant use case. There is also one compound included specifically for readers with the opposite goal, those who want to stimulate appetite for bulking, recovery, or other reasons. The two directions are different enough mechanically that they are worth keeping clearly separate.

1. Tirzepatide: The Dual-Agonist with the Strongest Weight-Loss Trial Data

Tirzepatide works by activating two separate receptors at once: the GLP-1 receptor, which stands for glucagon-like peptide-1, and the GIP receptor, which stands for glucose-dependent insulinotropic polypeptide. Think of these as two separate dials in your body's appetite-control system. Most earlier medications turned only one dial. Tirzepatide turns both, which researchers believe explains why its trial results have consistently outpaced single-receptor agents.

The clinical evidence here is as solid as it gets in this space. In the SURMOUNT-1 randomized controlled trial, participants using tirzepatide at the higher weekly doses lost an average of roughly 20 percent of their body weight over 72 weeks, and more than half of participants lost at least 20 percent. Standardized appetite scores, food cravings, and what researchers call disinhibited eating all decreased measurably in the trial. These are not surrogate markers; they are the actual experience of no longer wanting to eat as much.

How it produces that effect mechanically is worth understanding. GLP-1 agonism slows gastric emptying, meaning food stays in your stomach longer and fullness signals last longer. It also acts in the hypothalamus, the brain region that runs the hunger-satiety balance, where it quiets a population of neurons called AgRP neurons that drive eating. The GIP component adds a second route through the gut-brain axis that also reduces food intake and regulates how the body handles fat. Together, those two signals create a stronger and more sustained suppression of appetite than either pathway alone.

Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. It is available by prescription through standard clinics and telemedicine platforms, with eligibility criteria based on body mass index and related conditions. A head-to-head Phase 3b trial comparing it directly against semaglutide is currently ongoing.

Real-world reports from community forums echo the trial data. Users describe the effect as a fundamental shift in how food registers mentally, not just eating less but genuinely wanting less. Some users note that certain high-fat foods trigger nausea, which is consistent with the gastric-emptying mechanism. The side-effect profile is real and worth knowing: gastrointestinal effects, primarily nausea and some digestive disruption, are the most commonly reported, particularly early in use and when the dose increases.

2. Semaglutide: The Established Standard with the Longest Track Record

Semaglutide is a GLP-1 receptor agonist, the same receptor class that tirzepatide also targets, but it works through a single pathway rather than two. That distinction matters for understanding the evidence differences between them, but it does not diminish how strong semaglutide's own data is. It has been studied in humans for longer than any other compound in this field, with approval first for type 2 diabetes and then specifically for obesity management.

The randomized controlled trial evidence is extensive. A 2021 study in nearly 2,000 participants found that 61 percent of people using semaglutide at the approved weekly dose lost at least five percent of their body weight over 68 weeks, compared with 12 percent in the placebo group. Average weight loss across participants was roughly 15 percent of body weight. These numbers represent one of the most consistent and replicated findings in modern obesity medicine.

The mechanism mirrors what was described for tirzepatide's GLP-1 component: it binds the GLP-1 receptor, slows gastric emptying to extend fullness signals, and acts in the hypothalamus to suppress the AgRP neurons that promote eating while activating POMC neurons that signal satiety. The effect that users describe most often is not feeling full in a traditional sense but rather a quieting of the mental preoccupation with food. Multiple community reports describe it as the brain shutting off wanting to eat, which maps directly to what is happening at the level of those hypothalamic circuits.

Semaglutide is available in three forms: a once-weekly subcutaneous injection under well-known brand names for weight loss and diabetes, and an oral daily pill that is the only oral GLP-1 option currently on the market. All forms require a prescription. One real-world nuance worth noting: the appetite suppression is sometimes described as more abrupt than with other options, and some users report difficulty maintaining adequate protein intake because food desire disappears so completely. That is a practical consideration worth knowing before starting.

Side effects are similar to those across the GLP-1 class: nausea, gastrointestinal discomfort, and injection-site reactions are the most common. Semaglutide's long track record means its safety profile is better characterized than any investigational compound in this article.

3. Liraglutide: The First GLP-1 Approved for Chronic Weight Management

Liraglutide holds a specific historical position in this field: it was the first GLP-1 receptor agonist to receive FDA approval specifically for chronic weight management, back in 2014. It works through the same core mechanism as semaglutide, binding the GLP-1 receptor to reduce appetite and increase satiety, though it requires daily rather than once-weekly injection because it clears the body more quickly.

The clinical evidence is solid and drawn from multiple well-designed studies. A 2017 meta-analysis pooling five randomized controlled trials confirmed that liraglutide produced significantly higher rates of five-percent and ten-percent weight loss compared with placebo. Average weight loss across those trials landed in the five-to-ten percent range, meaningfully lower than what the weekly GLP-1 agents and tirzepatide achieve, but clinically significant and replicated across multiple independent studies.

One distinction that sets liraglutide apart from the other GLP-1 agents on this list is its approval for use in adolescents aged 12 and older. That regulatory designation reflects a separate body of clinical work in younger populations, making it the option with the most established evidence base for appetite management in that age group.

The daily injection requirement is a real practical difference from the weekly options. Users who find once-daily structure easier to adhere to report that consistently, and users who find the injection frequency burdensome often migrate toward weekly agents. The side-effect profile is similar to the rest of the class, with gastrointestinal effects being most common and generally most pronounced early in the dose-escalation period.

4. Retatrutide: The Triple Agonist in Late-Stage Clinical Development

Retatrutide is where the field is heading. It combines the same GLP-1 and GIP receptor agonism that tirzepatide uses with a third pathway: glucagon receptor agonism. That third element is the key differentiator. Glucagon receptor activation increases the body's metabolic rate, meaning retatrutide adds an energy-expenditure component on top of the appetite suppression that the first two mechanisms provide. The combination is being studied as a potential step beyond tirzepatide's already-strong results.

The Phase 2 trial data is striking. At higher weekly doses, participants lost an average of roughly 30 percent of their body weight, and more than 45 percent of those participants lost at least 30 percent. All participants at those doses lost at least five percent. These are not Phase 3 numbers yet, and full peer-reviewed Phase 3 data is still pending, but they represent the most dramatic appetite-suppression and weight-loss outcomes published for any compound in this field to date. A head-to-head comparison against tirzepatide called the TRIUMPH-5 trial is currently ongoing.

Retatrutide is investigational. It is not FDA-approved, it is not prescribable, and it is not available through any standard clinical or telemedicine channel. What exists in the community reporting space are anecdotal accounts from people who obtained it through research channels, and those reports mirror what the Phase 2 data suggests: rapid and significant appetite reduction, with users noting they can still enjoy eating but consume substantially less.

One nuance that comes up consistently in community accounts is a qualitative difference in how the appetite effect feels compared to semaglutide. Where semaglutide users often describe a near-complete quieting of food desire, some retatrutide users describe a reduction in cravings while still being able to enjoy a meal when they sit down to one. That distinction is subjective and the Phase 2 trial did not formally characterize it, but it recurs often enough in community discussion to be worth noting. Side-effect profiles in community reports are variable, with some users describing intense early reactions and others reporting minimal disruption.

5. Eloralintide: An Emerging Amylin-Pathway Option

Eloralintide works through a different mechanism than all the GLP-1 compounds above. It is an amylin mimetic, meaning it mimics a hormone called amylin that the pancreas releases naturally alongside insulin after meals. Amylin regulates appetite through a separate brain pathway from GLP-1, primarily by slowing the rate at which the stomach empties and by signaling fullness through areas of the brain stem involved in appetite rather than the hypothalamus directly. The case for an amylin mimetic is that it hits a second, complementary target, potentially adding to what GLP-1 agonism alone can accomplish.

Early clinical trial data showed roughly 20 percent weight loss, which puts eloralintide in a competitive range compared to semaglutide. Full Phase 3 data has not been published as of 2026, and the compound is not FDA-approved. What exists is early-stage human data that is genuinely promising and has attracted enough scientific attention that researchers are exploring amylin-pathway combination approaches to see whether the two mechanisms compound on each other.

Community discussion of eloralintide is less extensive than for the GLP-1 agents and retatrutide, reflecting that it is still primarily a pipeline story rather than a compound people are running in community protocols. It appears in the appetite-suppression conversation largely because practitioners and researchers watching the field are paying serious attention to the amylin pathway as a genuine next-wave mechanism. The honest summary is that the early data is real and interesting, but most readers will encounter this compound in clinical trial contexts rather than community use for now.

6. Cagrilintide Combined with Semaglutide: The Dual-Hormone Combination Approach

The combination of cagrilintide and semaglutide, sometimes referred to in trial literature as CagriSema, represents a different strategic approach from a single multi-receptor compound. Cagrilintide is an amylin analog, meaning it acts through the same general pathway described for eloralintide above, while semaglutide contributes GLP-1 receptor agonism. Running them together is a bet on hitting the appetite-control system through two complementary hormonal pathways simultaneously, similar in logic to tirzepatide's dual-receptor strategy but implemented as a combination rather than a single molecule.

A Phase 2 trial investigating the combination's effects on metabolism and appetite compared to diet alone is currently ongoing. Published data from that trial is not yet complete as of 2026, so the honest characterization here is preliminary and investigational. The mechanistic rationale is grounded in real biology, and the amylin-plus-GLP-1 pairing has attracted serious research investment. Neither cagrilintide alone nor the combination is FDA-approved.

Discussion in community settings is present but limited compared to the GLP-1 agents and retatrutide. Most of the conversation is at the practitioner and research level, tracking trial progress rather than user-reported protocol outcomes. For a reader building a picture of where the appetite-suppression field is heading, the CagriSema work represents a meaningful part of the landscape, and understanding that the amylin pathway is a genuine mechanistic frontier beyond GLP-1 is useful context regardless of where this specific combination ultimately lands.

7. GHRP-6: For Appetite Stimulation

GHRP-6 belongs on this list for a different reason than everything above. Where entries one through six are appetite suppressants, GHRP-6 does the opposite: it is used primarily to stimulate appetite, and it is included here because a meaningful share of people searching for peptides and appetite want to eat more, not less. Bodybuilders maintaining a caloric surplus during a hard bulk, people recovering from illness or surgery who have lost their appetite, and individuals managing conditions that suppress hunger all represent that use case.

GHRP-6 is a growth hormone-releasing peptide that acts on the ghrelin receptor, sometimes called the hunger receptor. Ghrelin is the hormone your body produces naturally to signal hunger. GHRP-6 activates that receptor artificially, producing a strong and noticeable increase in appetite. The appetite-stimulating effect is one of the compound's most consistently reported characteristics in community use, and it is the primary reason people in bulking communities reach for it.

No human clinical trial data has been published specifically evaluating GHRP-6 as an appetite stimulant in controlled research as of 2026. What exists is user-reported experience from community protocols, primarily in bodybuilding and fitness contexts, along with mechanistic research on ghrelin-receptor agonism in animal models that established how the pathway works. GHRP-6 is not FDA-approved and is classified as a research chemical. People use it, the mechanism is real, but the human trial record is essentially absent, and that gap is worth stating plainly.

The side-effect profile from community reports includes water retention, an intensity of hunger that some users find uncomfortable, and a cortisol and prolactin response that some users monitor over time. Anyone considering it should understand they are in research-chemical territory, meaning manufacturing standards, purity, and dosing accuracy are not subject to any regulatory process.

How These Peptides Compare

Frequently Asked Questions

Do the FDA-approved appetite peptides require a prescription?

Yes, tirzepatide, semaglutide, and liraglutide are all prescription medications and cannot be legally obtained without one. Eligibility is typically based on body mass index criteria, though the exact thresholds can vary by how a prescriber applies current clinical guidelines. Telemedicine platforms can prescribe these medications after a medical evaluation, which has made access significantly more convenient in recent years.

What is the difference between how semaglutide and retatrutide suppress appetite?

Semaglutide works through a single receptor pathway, and many users describe the effect as a near-complete quieting of food desire. Retatrutide adds GIP and glucagon receptor agonism on top of GLP-1, and some users report that the experience feels qualitatively different, with reduced cravings but more preserved enjoyment of food when they do sit down to eat. That distinction is based on user-reported experience and has not been formally characterized in trial data, so treat it as an observation rather than a clinical conclusion.

Are investigational compounds like retatrutide and eloralintide available to use now?

Not through any standard clinical or telemedicine channel. Retatrutide and eloralintide are investigational compounds that have not received FDA approval. The only way to access them within a regulated framework is through enrollment in an active clinical trial. Some community protocols involve research-chemical sources, but that places users outside any regulatory oversight for manufacturing quality, purity, or dosing accuracy.

What is the safety difference between FDA-approved and research-chemical appetite peptides?

FDA-approved compounds like tirzepatide, semaglutide, and liraglutide have published safety profiles drawn from large, long-duration trials, with manufacturing held to pharmaceutical standards. Research-chemical peptides, including GHRP-6, carry unknown manufacturing quality, unverified dosing, and no regulatory oversight. The FDA has issued specific warnings about products labeled for research purposes being sold for human use. The safety gap between the two categories is real and meaningful.

Can peptides be used for both appetite stimulation and suppression at different times?

In principle, these compounds work in opposite directions and serve fundamentally different purposes, so switching between them would require a clear rationale and ideally clinical guidance. The appetite-suppressing GLP-1 agents and appetite-stimulating GHRP-6 operate through distinct hormonal pathways, and their effects on the body extend well beyond hunger signals alone. The specifics of how each compound interacts with an individual's physiology, current medications, and health history are exactly what a personalized evaluation is built to address.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for appetite control in one place.